PATENT CLAIM ANALYSIS

Application Number: 15936209
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-08
Patent Classification: ["435", "375000"]

Abstract:
Provided is a method for isolating and proliferating autologous cancer antigen-specific CD8 +  T cells, and more particularly, a method for selecting an epitope recognized by CD8 +  T cells from autologous cancer antigens present in blood of individual cancer patients; and isolating autologous cancer antigen-specific CD8 +  T cells by using a peptide of the selected epitope, and a method of massively proliferating CD8 +  T cells by using the method. According to the present invention, it is possible to isolate autologous cancer antigen-specific CD8 +  T cells by using the peptide of the CD8 T cell epitope of the autologous cancer antigen present in blood of individual cancer patients instead of a heterologous antigen. Therefore, by using T cells recognizing the autologous cancer antigen, it is possible to effectively select and eliminate cancer cells derived from the cancer patient's own cells. Thus, T cells can be applied to treatment and alleviation of cancer diseases without side effects.

Claim (Index 17):
The method of  claim 12 , wherein the culturing step b) is performed for 12 to 16 days.

Metadata:
- Claim Count in Document: 62.0
- Percentile: 90.0
- Lexical Diversity: 2.56716
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['12010048', '11782264', '14364592', '14468326', '12691489']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6467298979789222
- 35 USC 102 Novelty (BERT): 0.5309699209976299
- Combined Prediction Score: 0.6351539002807931
- Mean Citation Score: 322.603438
- Max Citation Score: 368.12045
- Similarity Product: 284.0050117821515

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test